Can CDSCO Ignore Its Own Prosecution Guidelines? Legal Validity and Article 14 Challenge Explained

ABSTRACT

The DCC and CDSCO prosecution guidelines are not legally binding as a matter of positive law — they cannot override the strict liability provisions of the Drugs and Cosmetics Act, 1940 and have no statutory force equivalent to rules framed under Section 33 or directions issued under Section 33P. However, this does not mean they are entirely without legal consequence. Where CDSCO has consistently applied the screening committee process and written permission requirement before initiating prosecutions — and then selectively bypasses that process against a particular manufacturer — the doctrine of legitimate expectation and Article 14 of the Constitution provide grounds for challenge. This article examines the doctrine of legitimate expectation in Indian administrative law, its application to CDSCO’s enforcement practices, and the strategic litigation pathways available to manufacturers who face selective enforcement.

INTRODUCTION

In the earlier research establishing the non-binding character of DCC prosecution guidelines, a paradox emerged: if the guidelines have no force of law, why should any manufacturer care whether CDSCO followed them or not?

The answer lies in a set of constitutional doctrines — legitimate expectation and Article 14 non-arbitrariness — that operate not by validating the guidelines as law, but by requiring the government to treat similarly situated persons consistently. An administrative guideline that is invalid as a source of substantive law may still create a constitutional expectation of consistent application. A government body that departs from its own established practice without reason or notice acts arbitrarily — and arbitrary state action violates Article 14 of the Constitution of India.

This article develops this argument as a litigation strategy for pharmaceutical manufacturers who face prosecution that bypassed CDSCO’s own established process.

THE DOCTRINE OF LEGITIMATE EXPECTATION IN INDIAN LAW

Legitimate expectation is a doctrine of English origin, received into Indian administrative law through the Supreme Court’s jurisprudence beginning in the 1980s. In its simplest formulation: where a public authority has by its conduct, representations, or established practice created a reasonable expectation in a person that a particular procedure will be followed or a particular benefit will be granted, that authority is required — as a matter of procedural fairness — to either fulfil the expectation or give adequate reasons for departing from it.

The doctrine was recognised and applied by the Supreme Court in Council of Civil Service Unions v. Minister for the Civil Service [1985] AC 374 (UK, persuasive), and adopted in India in Attorney General of Hong Kong v. Ng Yuen Shiu [1983] 2 AC 629 (Privy Council, applied in Indian courts). The Supreme Court in Union of India v. Hindustan Development Corporation (1993) 3 SCC 499 fully embraced the doctrine, holding that legitimate expectation arising from established practice or representation could be enforced by courts.

In Managing Director, APSRTC v. P. Srinivasa Rao, the Supreme Court held that government is bound by its own circulars once operative — authorities cannot simply ignore them without challenge or withdrawal. The principle that the government is bound by its own circulars is ‘well settled’ in Indian law.

THE ARTICLE 14 NON-ARBITRARINESS DIMENSION

Article 14 of the Constitution of India guarantees equality before law and equal protection of the laws. The Supreme Court, in E.P. Royappa v. State of Tamil Nadu (1974) 4 SCC 3, dramatically expanded the Article 14 guarantee beyond formal equality to encompass non-arbitrariness: ‘Equality is antithetical to arbitrariness. In fact equality and arbitrariness are sworn enemies; one belongs to the rule of law in a republic while the other, to the whim and caprice of an absolute monarch.’

This means that even where CDSCO has the legal power to prosecute (which it undeniably does under Section 32 of the Act), it must exercise that power consistently and non-arbitrarily. If CDSCO follows the screening committee procedure for 99 manufacturers in the same factual situation and then bypasses it for the 100th — without explanation — the 100th manufacturer has an Article 14 challenge: not against the prosecution per se, but against the selective departure from established enforcement practice.

THE CRITICAL DISTINCTION: USING INVALID GUIDELINES TO ENFORCE EQUAL TREATMENT

The legitimate expectation/Article 14 argument is structurally different from the ultra vires argument:

The ultra vires argument: ‘The DCC guidelines are invalid; therefore, even where CDSCO follows them, they cannot lawfully constrain prosecution.’

The legitimate expectation argument: ‘The DCC guidelines are CDSCO’s own established practice; regardless of their legal validity, CDSCO must apply them consistently or justify its departure.’

These two arguments point in opposite directions: the manufacturer charged in a Category B case wants CDSCO to follow the guidelines (screening committee, written sanction) — using the established practice as a procedural shield. The public interest litigant who wants more prosecution wants courts to declare the guidelines ultra vires — so Drug Inspectors can prosecute without them.

Both arguments are simultaneously available and are not contradictory — they operate in different legal registers. The manufacturer argues: ‘Even if these guidelines are not law, you have made them your practice, and you must follow your own practice.’ The public interest litigant argues: ‘These guidelines are ultra vires and should not be followed at all.’

LIMITS OF LEGITIMATE EXPECTATION

The doctrine of legitimate expectation is subject to well-settled limitations that counsel must acknowledge:

First, legitimate expectation cannot enforce an ultra vires practice. Where the established practice is itself illegal — for example, CDSCO’s practice of applying a 70% assay threshold that departs from pharmacopoeial standards — courts will not enforce consistency in an illegal practice. The expectation of equal treatment in illegality is not protected.

Second, legitimate expectation does not override statutory duty. If CDSCO has a statutory obligation to prosecute — which it does, given the mandatory character of Sections 18 and 27 — a manufacturer cannot use legitimate expectation to permanently bar prosecution. At best, the doctrine provides a procedural remedy: require CDSCO to follow its established process before filing the complaint.

Third, the legitimate expectation must be reasonable and established by clear and consistent past practice. Ad hoc or occasional observance of the screening committee process does not create a legitimate expectation.

STRATEGIC IMPLICATIONS FOR LITIGATION

For pharmaceutical manufacturers facing prosecution, the following strategic positions follow from this analysis:

Where the screening committee process was bypassed: File a writ petition challenging the complaint as filed in violation of CDSCO’s own established enforcement procedure, relying on Article 14 and legitimate expectation. Seek stay of prosecution pending correction of procedural irregularity.

Where the screening committee process was followed for similarly situated competitors but not for the petitioner: File a writ petition alleging selective enforcement and discrimination under Article 14. The evidentiary burden is on CDSCO to justify the differential treatment.

Where CDSCO has published and consistently applied internal prosecution thresholds: Rely on those thresholds as creating legitimate expectations of consistent application — even if the thresholds are not statutory.

One important caveat: these arguments provide procedural remedies, not permanent shields. A successful writ petition may delay prosecution, require CDSCO to restart the process with the screening committee, or result in the prosecution being filed through proper channels. It does not result in permanent immunity from prosecution.

VII. CONCLUSION

The non-binding character of DCC and CDSCO prosecution guidelines does not make them legally irrelevant. Through the doctrine of legitimate expectation and Article 14 non-arbitrariness, manufacturers can use CDSCO’s own established practices as procedural weapons against selective or arbitrary enforcement. The key requirement is demonstrating a consistent, established practice that was departed from without justification in the petitioner’s case.

This doctrine sits at the intersection of administrative law and constitutional law — it is available only where the government has, through consistent practice, created a reasonable expectation that specific procedures will be followed. Where that expectation exists, courts will enforce it — not by validating the guidelines as law, but by requiring the government to treat its own practices as binding on its own conduct.

FAQ

1. Are CDSCO prosecution guidelines legally binding?
No. CDSCO prosecution guidelines do not have statutory force under the Drugs and Cosmetics Act, 1940 and cannot override its strict liability provisions. They are administrative in nature and not equivalent to rules framed under Section 33 or directions under Section 33P.

2. If the guidelines are not binding, can they still be used in court?
Yes. Even though they are not legally binding, they can be invoked through constitutional principles like legitimate expectation and Article 14 of the Constitution of India to challenge arbitrary or inconsistent enforcement.

3. What is the doctrine of legitimate expectation in this context?
It means that if the Central Drugs Standard Control Organization (CDSCO) has consistently followed a particular procedure—such as screening committee approval—manufacturers can expect that the same procedure will be followed in their case. A sudden deviation without justification can be challenged.

4. How does Article 14 apply to CDSCO prosecutions?
Article 14 ensures equality and prohibits arbitrary state action. If CDSCO follows a procedure for most manufacturers but selectively bypasses it for one, that manufacturer can challenge the action as arbitrary and discriminatory.

5. Can a manufacturer stop prosecution entirely using these arguments?
No. These arguments provide procedural relief, not complete immunity. Courts may require CDSCO to follow proper procedure or reconsider the case, but they do not permanently bar prosecution.

6. What is the difference between ultra vires and legitimate expectation arguments?

• Ultra vires argument: The guidelines are invalid and should not be followed at all.
• Legitimate expectation argument: Even if not legally binding, CDSCO must follow them consistently if they form an established practice.

7. Can legitimate expectation be claimed in all cases?
No. It applies only where there is clear, consistent, and established practice. Occasional or inconsistent use of a procedure does not create a legitimate expectation.

8. What are the limitations of using legitimate expectation?

• It cannot enforce an illegal practice
• It cannot override statutory duties
• It requires consistent past conduct by the authority

9. When can a manufacturer file a writ petition against CDSCO?
A writ petition can be filed when:

• Established procedures (like screening committee review) are bypassed
• There is selective enforcement compared to similarly situated entities
• CDSCO departs from its own consistent practice without justification

10. What is the practical benefit of this legal strategy?
It allows manufacturers to:

• Challenge arbitrary prosecution
• Delay or pause proceedings
• Force CDSCO to follow fair and consistent procedures

REFERENCES

[1] E.P. Royappa v. State of Tamil Nadu, (1974) 4 SCC 3 — Supreme Court of India (Article 14 non-arbitrariness).  https://indiankanoon.org/doc/1733604/

[2] Union of India v. Hindustan Development Corporation, (1993) 3 SCC 499 — Supreme Court of India (legitimate expectation).  https://indiankanoon.org/doc/597229/

[3] Managing Director, APSRTC v. P. Srinivasa Rao — Supreme Court of India (government bound by its own circulars).  https://supremetoday.ai/issue/The-Principle-that-the-Government-is-Bound-by-its-own-Circulars-is-Well-Settled

[4] Sant Ram Sharma v. State of Rajasthan & Anr., AIR 1967 SC 1910 — Supreme Court of India.  https://lawlens.in/doc/5aa43bbb-095a-4ff0-96ac-f93abfc56ed5

[5] G.J. Fernandez v. State of Mysore & Ors., AIR 1967 SC 1753 — Supreme Court of India.  https://www.legitquest.com/case/gj-fernandez-v-state-of-mysore-others/4C41

[6] The Drugs and Cosmetics Act, 1940, Sections 16, 18, 27, 32, 33P.  https://www.indiacode.nic.in/bitstream/123456789/15278/1/drug_cosmeticsa1940-23.pdf

[7] DCC Guidelines for Taking Action on Samples of Drugs Declared Spurious or NSQ — CDSCO (2008).  https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/Consumer_Section_PDFs/DCC_Guidelines_Spurious_Drugs.pdf

[8] Dinesh Thakur & Prashant Reddy T., ‘A Report on Fixing India’s Broken Drug Regulatory Framework’ (June 2016).  https://spicyip.com/wp-content/uploads/2016/06/Report_India-Drug-Regulatory-Framework_June-2016.pdf